Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trazodone and priapism.

M D Warner, C A Peabody, H A Whiteford

    The Journal of Clinical Psychiatry
    |June 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Priapism, a prolonged erection, is linked to trazodone use, particularly within the first 28 days and at lower doses. Patients should be aware of this risk and seek medical attention for unusual erectile issues.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The cost of mental disorders: a systematic review.

    Epidemiology and psychiatric sciences·2020
    Same author

    Perceived need and barriers to adolescent mental health care: agreement between adolescents and their parents.

    Epidemiology and psychiatric sciences·2019
    Same author

    A profile of Australian mental health carers, their caring role and service needs: results from the 2012 Survey of Disability, Ageing and Carers.

    Epidemiology and psychiatric sciences·2018
    Same author

    Intersectoral policy for severe and persistent mental illness: review of approaches in a sample of high-income countries.

    Global mental health (Cambridge, England)·2017
    Same author

    Post-traumatic stress disorder and major depression in conflict-affected populations: an epidemiological model and predictor analysis.

    Global mental health (Cambridge, England)·2017
    Same author

    A systematic review and meta-regression of the prevalence and incidence of perinatal depression.

    Journal of affective disorders·2017
    Same journal

    Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

    The Journal of clinical psychiatry·2026
    Same journal

    Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

    The Journal of clinical psychiatry·2026
    Same journal

    Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

    The Journal of clinical psychiatry·2026
    Same journal

    Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

    The Journal of clinical psychiatry·2026
    Same journal

    The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

    The Journal of clinical psychiatry·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Urology
    • Drug Safety

    Background:

    • Trazodone is a commonly prescribed antidepressant.
    • Priapism is a known, albeit rare, adverse effect associated with trazodone.
    • Understanding the specific risk factors for trazodone-induced priapism is crucial for patient safety.

    Purpose of the Study:

    • To review the association between trazodone and priapism using Food and Drug Administration (FDA) data.
    • To identify potential risk factors, such as timing of onset and dosage, for trazodone-associated priapism.
    • To inform clinical practice and patient counseling regarding this adverse event.

    Main Methods:

    • Analysis of adverse event reports submitted to the Food and Drug Administration (FDA).
    • Review of case data to determine the temporal relationship between trazodone initiation and priapism.

    Related Experiment Videos

  • Examination of dosage information in reported cases of priapism.

    • Main Results:

    • Priapism associated with trazodone appears most likely to occur within the initial 28 days of treatment.
    • The majority of reported priapism cases occurred with trazodone doses of 150 mg/day or less.
    • All age demographics are susceptible to developing priapism while taking trazodone.

    Conclusions:

    • Trazodone use carries a risk of priapism, particularly early in treatment and at lower doses.
    • Healthcare providers should counsel patients on the potential for priapism and advise discontinuation if unusual erectile problems arise.
    • Vigilance for priapism is warranted across all patient populations prescribed trazodone.